New peptide aims to flush out hidden HIV in early trial

NCT ID NCT06799650

Ongoing Disease control Sponsor: Federal University of São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests whether adding Gammora® (a peptide) to standard antiretroviral therapy can reduce the hidden HIV reservoir in people newly diagnosed with HIV. Forty participants who have never taken HIV drugs will be randomly assigned to receive either Gammora® plus standard drugs or standard drugs alone. The study measures changes in HIV DNA levels and cell death markers over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gammora® (a peptide) plus standard antiretroviral drugs (Tenofovir, 3TC, Darunavir, Ritonavir)
What this could lead to: If successful, this could point toward a way to shrink the hidden HIV reservoir, potentially leading to better long-term control of the virus.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 40 participants. The results may not be generalizable, and the treatment may not significantly reduce the HIV reservoir or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease HIV Seropositivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV SEROPOSITIVITY

Contacts and locations

Locations

RDSS

São Paulo, São Paulo, 04039-032, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.